Varian has received approval from China’s National Medical Product Administration for its Halcyon system to treat cancer.

The Halcyon system is designed to treat cancer patients with radiotherapy to treat lung, prostate, breast, head & neck and other forms of cancer. The system has a human-centered and user-friendly design to improve clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training and automate treatment.

“We are very excited to further expand Halcyon’s global availability,” said Chris Toth, president Varian Oncology Systems. “With the most recent announcement by the Chinese government for expanding Category B licenses and enabling County hospital oncology services availability, Halcyon is a perfect fit.”

Halcyon has already received clearance and approval in the U.S., Europe, Japan and Brazil and has received an Anatomic Energy Regulatory Board Certificate for Import and Supply. It has also received Type Approval in India and TFDA approval in Taiwan since it was launched in May 2017.